Related Experiment Videos
Interleukin-12: potential role in cancer therapy
1Department of Oncology, Hoffmann-La Roche, Inc. Nutley, New Jersey, USA.
Important Advances in Oncology
|January 1, 1995
Summary
Interleukin-12 (IL-12) enhances cell-mediated immunity and shows therapeutic potential in preclinical models of cancer and infection. Clinical trials are underway to assess its efficacy and safety in humans.
Area of Science:
- Immunology
- Oncology
- Infectious Diseases
Background:
- Interleukin-12 (IL-12) is a cytokine crucial for cell-mediated immunity, particularly involving T and NK cells.
- Endogenous IL-12 production is vital for host defense against intracellular pathogens.
- Recombinant IL-12 (rIL-12) demonstrates significant therapeutic effects in murine models of tumors and infections.
Purpose of the Study:
- To evaluate the therapeutic potential of IL-12 in preclinical models.
- To assess the tolerability and pharmacokinetics of IL-12.
- To initiate Phase I clinical trials for IL-12 in human malignancies.
Main Methods:
- Administration of rIL-12 in various murine disease models.
- Monitoring of therapeutic effects in tumor and infectious disease models.
- Conducting Phase I clinical trials for safety and tolerability in cancer patients.
Main Results:
- rIL-12 showed dramatic therapeutic effects in preclinical tumor and infectious disease models.
- IL-12 exhibits a favorable serum half-life, allowing dosing flexibility.
- IL-12 was well tolerated at efficacious doses in murine models.
Conclusions:
- IL-12 demonstrates significant therapeutic promise in preclinical settings.
- The favorable pharmacokinetic profile of IL-12 supports its clinical development.
- Clinical utility in humans requires further investigation through ongoing Phase I trials.